UNRESECTABLE SOLID NEOPLASM
Clinical trials for UNRESECTABLE SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for UNRESECTABLE SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Vaccine-Immunotherapy combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase study tested a vaccine (p53MVA) plus the drug pembrolizumab in 11 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to see if the combination is safe and can boost the immune system to attack cancer cells. Participant…
Matched conditions: UNRESECTABLE SOLID NEOPLASM
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 06:19 UTC
-
New hope for Hard-to-Treat cancers: targeted immunotherapy trial launches
Disease control OngoingThis study tests whether the immunotherapy drug nivolumab can help control cancer in people with metastatic or inoperable solid tumors that have a specific genetic change (ARID1A mutation) and a protein marker (CXCL13). Sixteen participants will receive nivolumab to boost their i…
Matched conditions: UNRESECTABLE SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Promising drug cocktail targets Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests a combination of two drugs, veliparib and topotecan, in people with solid tumors or ovarian cancer that has returned after initial treatment. The goal is to find the safest dose and see if the combo can shrink tumors. About 88 adults are taking part in this early…
Matched conditions: UNRESECTABLE SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests whether adding a drug called methoxyamine (TRC102) to standard chemotherapy can help shrink tumors in people with advanced solid tumors or mesothelioma that have not responded to other treatments. The goal is to make cancer cells more sensitive to chemo. About 30…
Matched conditions: UNRESECTABLE SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New hope for rare cancers: immune-boosting drug shows promise
Disease control OngoingThis study tests a drug called pembrolizumab in 157 people with rare tumors that cannot be removed by surgery or have spread. The drug helps the immune system fight cancer by blocking a protein that slows it down. The main goal is to see if the drug can stop tumors from growing f…
Matched conditions: UNRESECTABLE SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 24, 2026 16:07 UTC